You just read:

Statement by Douglas Throckmorton, M.D., Deputy Center Director for Regulatory Programs in FDA's Center for Drug Evaluation and Research, on new opioid analgesic labeling changes to give providers better information for how to properly taper patients who are physically dependent on opioids

News provided by

U.S. Food and Drug Administration

Apr 09, 2019, 14:42 ET